INTRODUCTION
In the budding yeast, Saccharomyces cerevisiae, it has been possible to isolate cell division cycle (cdc) mutations which disrupt the cell division cycle in a stage-specific manner (1-4). Studies of cdc mutants have led to the formulation of a model where the events of cell division are organized into a number of interrelated dependent pathways (2,4-6). Because all pathways diverge from Gl, cell division can, in theory, be controlled at a single point within this interval. Yeast cells deprived of an essential nutrient (7, 8) or responding to mating pheromone (9) cease from further division cycles and become synchronous at a point in Gl which has been designated "start" (2) . "Start" is thought to be the stage, therefore, where cell division is controlled. This report is part of an ongoing genetic and molecular analysis of "start" with the aim of elucidating division control at the molecular level.
ate mutations in four unlinked complementation groups, CDC28, CDC36, CDC37, and CDC39, arrest cells at start (2,3). It is therefore likely that the products of the genes defined by these complementation groups play a role in the division control process. For this reason, the genes were cloned (10,11) and then subjected to DNA sequence analysis. The ONA sequence of one of these start genes, CDC28, has been reported (12) . The inferred amino acid sequence of the CDC28 gene product is homologous to several vertebrate protein kinases, including those encoded by members of the src_ oncogene family (12) . Furthermore the CDC28 gene product has been shown to have a protein kinase activity in an immune complex assay (13) . These results suggest that protein phosphorylation may play an important role in control of cell division in yeast. The isolation and transcriptional characterization of three other start genes CDC36, CDC37, and CDC39 have previously been reported (11) . The inferred amino acid sequence of the CDC36 gene has been reported to have significant homology to the CDC4 product, also required early in the yeast cell division cycle, and to the product of the transformation-specific sequence of avian erythroblastosis virus E26, ets (14) . In virus E26, the ets sequence is linked in frame with &gag and myb E in the tripartite structure 5'-Agag-myb E -ets-3', comprising the E26 transforming oncogene (14) . The CDC36 gene product has homology to the 149 residue C-terminal portion of the CDC4 gene product, and to a 206 residue region from the middle of the ets_ product (14) . These data suggest a possible relationship between genes involved in yeast division control and vertebrate proto-oncogenes.
We report here the nucleotide sequence of the CDC36, CDC37, and CDC39 genes, and an analysis of the 5' and 3 1 untranslated regions of these, as well as of the CDC28 gene, for consensus sequences postulated to be transcriptional or translational signals, or to be involved in mRNA processing. Secondary structures for the inferred amino acid sequences of the four genes under study have been predicted according to the method of Chou and Fasman (15,16), and protein hydropathicities (an estimate of hydrophobicity) determined by the method of Kyte and Ooolittle (17). The codon usage biases (18) for these genes have been examined in relation to the abundancies of the corresponding mRNAs in the cell.
MATERIALS AND METHODS

DNA Sequence Analysis
The CDC36, CDC37, and CDC39 genes were sequenced by the M13-dideoxy method of Sanger ^ ^J_. (19) used in conjunction with M13 phages (20) . DNA deletions were obtained either by progressive digestion with Bal31 nuclease (12), or the sequential action of Exonuclease III from £. coli and SI nuclease from Aspergillus (21), and sequenced directly. When Bal31 was used, deletions were initiated at a centrally located unique restriction site and deletion end points were juxtaposed to the sequencing primer by digestion with a restriction enzyme which cleaves at a proximal site in the cloning polylinker segment followed by religation (12). Bal31 digestions were done at 30° using 1 unit Bal31 (BRL) per ug of DNA at a concentration of .02 ug DNA/ul of reaction mix, in 600 mM NaCl, 20 mM Tris-HCl (pH 8 ) , 12 mM CaCl 2 , 12 mM MgCl 2 , and 1 mM EDTA. These conditions resulted in a degradation rate of approximately 100 bp per end per minute. Depending on the length of the ONA sequence of interest and the extent of digestion desired, in some cases several time points of Bal31 digestion were combined into a single pool. Each pool of DNA was extracted with phenol, precipitated by addition of ethanol, and digested with an appropriate restriction enzyme to cleave in the cloning polylinker segment, in order to remove the residual DNA fragment between the sequencing primer and the site of initiation of Bal31 digestion. This sequencing method requires having a "buffer" region of dispensable DNA in this region. A 5 minute incubation at 65° followed. Each pool of DNA was then treated for 10 minutes at room temperature with 4 units of E_. coli DNA Polymerase I (large fragment; BRL) per yg DNA at a concentration of .05 ug DNA/pl reaction mix in 13 mM each of Tris-HCl (pH 7.5), NaCl, MgCl 2 , and DTT, and 0.1 mM each of deoxynucleotide triphosphate, followed by extraction with phenol and precipitation by addition of ethanol. Ligations were performed at room temperature for 6-18 hours with 2 units T4 DNA Ligase (BRL) per yg DNA at a concentration of .04 u9 DNA/ul reaction mix in 1 mM ATP, 66 mM Tris-HCl (pH 7.5), 6.6 mM MgCl 2 , 10 mM DTT, and 100 ug/ml bovine serum albumin. Each DNA pool was then transfected into competent JM103 or JM101 cells (20) . Deletion end points were aligned by means of restriction mapping so that appropriate phages could be chosen for sequencing. The procedure employed to produce random deletions for sequencing using the sequential action of Exonuclease III and SI nuclease was that of Henikoff (21). We found that for this procedure it is mandatory to use M13 replicative form DNA prepared by a method which incorporates an alkaline lysis step, such as that of IshHorowicz and Burke (22) . DNA prepared otherwise is labile to Exonuclease III digestion throughout the molecule and cannot be kept intact after Exonuclease III treatment. All DNA sequences were determined more than once, either on separate strands or from different endpoints on the same strand 
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2350 2400 Fig. 5 ) . The carboxy-terminal segment of the wild type CDC37 gene product that is missing in the truncated version includes most of the acidic portion of the wild type protein, having an excess of 13 acidic over basic residues. In both cases the gene products are functional to the extent that they are able to complement the respective _ts_ allele when on a plasmid containing an arsl replicator. Such plasmids are normally present at several copies per cell. We do not know for either gene whether the truncated form is capable of complementing the corresponding ^s_ mutation when present at one copy per cell, or whether, at any copy number, a phenotype consistent with the absence of a particular domain of the protein might be observed. For instance, the cdc37-l ts mutation has a weak kar phenotype in addition to the cell cycle defect (25), and the truncated CDC37 gene might complement one defect but not the other.
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We have reported the inferred ami no acid sequences of the CDC36, CDC37, and CDC39 genes (Figs. 4, 5, and 6 ) . The CDC28 and CDC36 gene products have previously been reported to be homologous to vertebrate oncogenes (12, 14) . A similar computer search has to date yielded no proteins homologous to the have a high alpha-helix content (26) . While the implications of the predicted high alpha-helix content, and thus highly organized structure, of the CDC37 and CDC39 proteins must await further study, it is interesting to speculate that they may be structural proteins similar to intermediate filament proteins. This idea is particularly attractive in light of observations that the CDC28 protein appears to be associated with the yeast cytoskeleton (27) , and of suggestive genetic evidence that the functions of the CDC37 and CDC28 gene products may be related (27) . cdc37/cdc28 double mutants are barely viable at permissive temperature for each of the individual mutations, and may be inviable for some alleles, suggesting that the respective gene products interact.
Hydropathicities have been determined for the CDC28, CDC36, CDC37, and CDC39 gene products according to the method of Kyte and Doolittle (17), which progressively evaluates the hydrophilicity and hydrophobicity of a protein along its amino acid sequence. These data are expressed in Table 1 
